155 results
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
7 May 24
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
8:05am
expanded label for ZYNRELEF,” said Craig Collard, Chief Executive Officer of Heron.
Business Highlights
The ZYNRELEF Vial Access Needle (“VAN”) program
8-K
EX-99.1
w7doe 7gw7m64t70h3y
12 Mar 24
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
4:10pm
8-K
EX-99.1
zff2ja bh
24 Jan 24
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
8:01am
8-K
EX-99.1
7ao 54qo9
11 Jan 24
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-99.1
2sh2syixzc0
14 Nov 23
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
4:10pm
424B3
bq0caqvfx
5 Sep 23
Prospectus supplement
9:14pm
8-K
EX-10.1
a9q etn4j9s
24 Jul 23
Heron Therapeutics Announces $30 Million Private Placement Financing
9:12am
8-K
EX-99.1
qe0 07h7g7di
29 Dec 22
Other Events
9:10am